Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study

被引：7

作者：

Bongiovanni, M ^{[1
]}

Bini, T ^{[1
]}

Tordato, F ^{[1
]}

Cicconi, P ^{[1
]}

Melzi, S ^{[1
]}

Repetto, D ^{[1
]}

Sollima, S ^{[1
]}

Rusconi, S ^{[1
]}

Monforte, AD ^{[1
]}

机构：

[1] Univ Milan, Luigi Sacco Hosp, Inst Infect & Trop Dis, I-20157 Milan, Italy

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2003年 / 51卷 / 01期

关键词：

D O I：

10.1093/jac/dkg045

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The immunovirological outcome of lopinavir/ritonavir was evaluated in 70 antiretroviral-experienced HIV patients; at baseline, median CD4+ cell count was 218 cells/mm(3) and median plasma viraemia 4.58 log(10) copies/mL. After 12 months, we observed an increase in CD4+ cell count to 322 cells/mm(3) (P = 0.0001) and a decrease in plasma viraemia to 2.35 log(10) copies/mL (P = 0.0001). Four patients discontinued lopinavir/ritonavir during observation. Among metabolic parameters, only triglyceride concentrations increased during treatment (P = 0.02). Twenty-six patients had a genotypic resistance test at baseline; four had greater than or equal to6 mutations known to reduce susceptibility to lopinavir/ritonavir. Undetectable plasma viraemia was obtained only in patients with less than or equal to5 mutations (61.9%).

引用

页码：171 / 174

页数：4

共 6 条

[1] Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].

Benson, CA ;

Deeks, SG ;

Brun, SC ;

Gulick, RM ;

Eron, JJ ;

Kessler, HA ;

Murphy, RL ;

Hicks, C ;

King, M ;

Wheeler, D ;

Feinberg, J ;

Stryker, R ;

Sax, PE ;

Riddler, S ;

Thompson, M ;

Real, K ;

Hsu, A ;

Kempf, D ;

Japour, AJ ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607

[2]

HICKS C, 2001, 8 EUR C CLIN ASP TRE

[3]

ISACSON J, 2002, 9 C RETR OPP INF SEA

[4]

RUIZ L, 2002, 9 C RETR OPP INF SEA

[5] ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease [J].

Sham, HL ;

Kempf, DJ ;

Molla, A ;

Marsh, KC ;

Kumar, GN ;

Chen, CM ;

Kati, W ;

Stewart, K ;

Lal, R ;

Hsu, A ;

Betebenner, D ;

Korneyeva, M ;

Vasavanonda, S ;

McDonald, E ;

Saldivar, A ;

Wideburg, N ;

Chen, XQ ;

Niu, P ;

Park, C ;

Jayanti, V ;

Grabowski, B ;

Granneman, GR ;

Sun, E ;

Japour, AJ ;

Leonard, JM ;

Plattner, JJ ;

Norbeck, DW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3218-3224

[6] Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy [J].

Tsuchiya, K ;

Matsuoka, S ;

Hachiya, A ;

Yasuoka, A ;

Tachikawa, N ;

Kikuchi, Y ;

Genka, I ;

Teruya, K ;

Kimura, S ;

Oka, S .

AIDS, 2001, 15 (09) :1183-1184

← 1 →